Date | Title | Description | |
---|---|---|---|
22 Jun 2021 | On significant placements in financial instruments | Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. | Download |
29 Apr 2021 | On business and financial situation | The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States. | Download |
12 Apr 2021 | On business and financial situation | The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. | Download |
02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
02 Mar 2021 | On business and financial situation | The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
Pages
Date | Title | Description | |
---|---|---|---|
01 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 23 February and 29 February 2024 | Download |
27 Feb 2024 | Annual Corporate Governance Report | ROVI releases the 2023 Annual Corporate Governance Report | Download |
27 Feb 2024 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2023 annual report regarding remuneration of the members of the Board of Directors. | Download |
23 Feb 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 16 February and 22 February 2024 | Download |
16 Feb 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 9 February and 15 February 2024 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
08 Oct 2018 | Share capital increases and reductions | Information on the registration in the Commercial Registry of Madrid of the notarial deed regarding the capital increase | Download |
05 Oct 2018 | Buy-back programmes, stabilisation and treasury stock | Information about the possibility that Jefferies International Limited carries out stabilisation transactions within the framework of the capital increase excluding pre-emptive subscription rights of the existing shareholders of Laboratorios Farmacéuticos Rovi, S.A. | Download |
04 Oct 2018 | Share capital increases and reductions | Directors’ Report and Independent Expert Report related to capital increase excluding preferential subscription rights | Download |
04 Oct 2018 | Liquidity contracts and specialists | The Company informs that has temporarily suspended liquidity agreement with JB Capital Markets, Sociedad de Valores, S.A.U. | Download |
04 Oct 2018 | Share capital increases and reductions | Information on price fixing and outcome of the private placement related to capital increase addressed to institutional investors, excluding preferential subscription rights | Download |